Thank you, Mr. Chair, for the question.
I was intrigued by some of the comments that were provided, because while we may have summarized that, yes, we are supportive of the status quo, we are supportive of a science-based, rigorous system when it comes to the new substance notification. We're very pleased with how that process works, as it is predictable and rigorous, and we're pleased that it also works for substances in Food and Drugs Act products.
I was a little bit surprised about the comments with respect to confidentiality, and I didn't understand some of the concerns. I would put that forward as something that maybe we could further explore, since CCSPA believes the powers within CEPA provide provisions to protect confidential test data, but also to provide information to people who wish to ask for that information, and that's through the Access to Information Act. It's my understanding that if a notifier makes a submission to the department and designates everything as confidential—test information or confidential business information—there are still pieces within the submission that can be accessible through the Access to Information Act.